We assessed the short and long-term efficacy and safety of the lipid lowering drugs, nicotinic acid, and the HMG-CoA reductase inhibitor, lovastatin, in combination with cholestyramine in four renal transplant patients. Combination therapy with cholestyramine failed to lower the TC and LDL to the levels recommended by the NCEP guidelines.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
nicotinic acid
8
lovastatin combination
8
combination cholestyramine
8
cholestyramine renal
8
renal transplant
8
transplant patients
8
effects nicotinic
4
acid lovastatin
4
patients assessed
4
assessed short
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!